Alagebrium chloride, a novel advanced glycation end-product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model

Korean Circulation Journal

Volumn 40, Issue 10, 2010, Pages 520-526

  Kim, Jin Bae ^a   Song, Byeong Wook ^a   Park, Sungha ^a   Hwang, Ki Chul ^a   Cha, Bong Soo ^a   Jang, Yangsoo ^a   Lee, Hyun Chul ^a   Lee, Moon Hyoung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Advanced glycation end products; Alagebrium; Neointimal hyperplasia

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY INJURY; CELL PROLIFERATION; CONNECTIVE TISSUE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES; VASCULAR SMOOTH MUSCLE;

EID: 78649411753     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2010.40.10.520     Document Type: Article

References (23)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. Circulation 1979;59:8-13.
2. Ha JK, Han DC, Hwang KW, et al. Metabolic syndrome and risk of in-stent restenosis: clinical outcomes in patients undergoing percutaneous coronary intervention. Korean Circ J 2007;37:567-73.
3. Park JS, Seok JH, Hong GR, Shin DG, Kim YJ, Shim BS. Types of instent restenosis and predictive factors for diffuse type in-stent restenosis. Korean Circ J 2001;31:1135-41.
4. Nielsen TT, Bøtker HE. Percutaneous coronary intervention in diabetic patients: a problem? Horm Metab Res 2005;37(Suppl 1):83-9.
5. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
6. Vaitkevicius PV, Lane M, Spurgeon H, et al. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 2001;98:1171-5.
7. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes induced myocardial structural changes. Circ Res 2003;92:785-92.
8. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride(ALT-711), a novel glucose cross link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005;11:191-5.
9. Cooper ME. Impotance of advanced glycation end products in diabetes associated cardiovascular and renal disease. Am J Hypertens 2004;17:31S-8S.
10. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-69.
11. Kass DA, Shapiro EP, Kaawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end product crosslink breakers. Circulation 2001;104:1464-70.
12. Wolffenbulttel BH, Boulanger CM, Crijns FR, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998;95:4630-4.
13. Ettenson DS, Gotlieb AI. Centrosomes, microtubules, and microfilaments in the reendothelialization and remodeling of double-sided in vitro wound. Lab Invest 1992;66:722-33.
14. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest 1994;93:1243-9.
15. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury: I. smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33.
16. Sakaguchi T, Yan SF, Yan SD, et al. Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 2003;111:959-72.
17. Naka Y, Bucciarelli LG, Wendt T, et al. RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 2004;24:1342-9.
18. Shim CY, Park S, Yoon SJ, et al. Association of RAGE gene polymorphisms with in-stent restenosis in non-diabetic Korean population. Cardiology 2007;107:261-8.
19. Susie D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004;19:336-40.
20. Forbes JM, Yee LT, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004;53:1813-23.
21. Zhuo Z, Wang K, Penn MS, et al. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 2003;107:2238-43.
22. Yue TL, Bao W, Gu JL, et al. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 2005;54:554-62.
23. Park S, Lim S, Chang W, et al. The inhibition of insulin-stimulated proliferation of vascular smooth muscle cells by rosiglitazone is mediated by the Akt-mTOR-P70S6K pathway. Yonsei Med J 2008;49:592-600.